Aleksandra M. Michalowski, M.Sc., Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 37, Room 3134B
- Bethesda, MD 20892
- 240-760-6938
- MichaloA@mail.nih.gov
RESEARCH SUMMARY
Dr. Michalowski develops biostatistical and bioinformatic approaches for the design and analysis of preclinical cancer research experiments. Her primary focus is genomic studies, which include integration and biological interpretation of large-scale transcriptional signatures from cancer models and patients across a variety of cancer types (multiple myeloma, breast cancer, melanoma and non-melanoma skin cancers, prostate cancer, and lung cancer), modeling of genomic networks, analysis workflows for next-generation sequencing data, and preclinical development of predictive signatures for cancer treatments. Her most recent project involves development of new algorithms for screening of anti-cancer synergistic drug combinations based on high-throughput in vitro assays.
Areas of Expertise
Aleksandra M. Michalowski, M.Sc., Ph.D.
Research
Dr. Michalowski develops biostatistical and bioinformatic approaches for the design and analysis of preclinical cancer research experiments. Her primary focus is genomic studies, which include integration and biological interpretation of large-scale transcriptional signatures from cancer models and patients across a variety of cancer types (multiple myeloma, breast cancer, melanoma and non-melanoma skin cancers, prostate cancer, and lung cancer), modeling of genomic networks, analysis workflows for next-generation sequencing data, and preclinical development of predictive signatures for cancer treatments. Her most recent project involves development of new algorithms for screening of anti-cancer synergistic drug combinations based on high-throughput in vitro assays.
Dr. Michalowski conducts collaborative research within the Laboratory of Cancer Biology and Genetics, the Biometric Research Branch (DCTD), and the National Center for Advancing Translational Sciences (NCATS) at NIH. Inventions Gene expression signatures of neoplasm responsiveness to therapy. PCT Application No. PCT/US2012/064693 NIH (DHHS) Reference No. E-013-2012/0-PCT-02 National stage filing in progress.
Publications
GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells
Investigation into diagnostic agreement using automated computer-assisted histopathology pattern recognition image analysis
A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer
Biography
Aleksandra M. Michalowski, M.Sc., Ph.D.
Dr. Aleksandra M. Michalowski received her M.Sc. and Ph.D. in biological sciences from the University of Adam Mickiewicz (UAM) in Poznan, Poland. She completed her postdoctoral training under Dr. Richard Simon at the Biometric Research Branch, Division of Cancer Treatment and Diagnosis, NCI, where she conducted research focusing on statistical analysis and computational programming in cancer genomics. Dr. Michalowski joined the Laboratory of Cancer Biology and Genetics in 2005 and was appointed to the position of Staff Scientist in 2011.